Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7481 pages
Showing 6351 - 6400BRAF Inhibition Successful in Relapsed/Refractory BRAF V600E–Mutant Hairy Cell Leukemia
In two phase II studies reported in The New England Journal of Medicine, Tiacci et al found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia who relapsed after treatment with a purine analog or who had...
ASCO Clinical Practice Guideline Update: Systemic Therapy for Stage IV NSCLC
As reported in the Journal of Clinical Oncology by Masters et al, ASCO has issued a clinical practice guideline update on systemic therapy for stage IV non–small cell lung cancer (NSCLC). Recommendations are based on an update committee systematic review of randomized controlled trials...
New Agent Targeting Epigenetic Modifications Shows Activity in Advanced Cancer
In a dose-escalation phase I study reported in The Lancet Oncology, Reid et al found that RRx-001, a representative of a new class of compounds called dinitroazetidines (sourced from the aerospace industry) that act on the tumor microenvironment, had activity in advanced cancers and a promising...
Final Results of NO16968 Trial Show Improved Overall Survival With Adjuvant XELOX vs Bolus 5-FU/Leucovorin in Stage III Colon Cancer
As reported by Schmoll et al in the Journal of Clinical Oncology, the final results of the phase III NO16968 trial showed that adjuvant therapy with XELOX (capecitabine, oxaliplatin) improved overall survival vs fluorouracil (5-FU)/leucovorin in patients with resected stage III colon cancer....
Improved Overall Survival With FOLFOXIRI/Bevacizumab vs FOLFIRI/Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer
In an updated analysis of the Italian phase III TRIBE trial reported in The Lancet Oncology, Cremolini et al found that FOLFOXIRI (fluorouracil [5-FU], leucovorin, oxaliplatin, irinotecan) plus bevacizumab (Avastin) significantly prolonged overall survival in patients with unresectable metastatic...
Dose Equivalence Analysis Indicates Reduced Risk of Late Heart Failure With Daunorubicin vs Doxorubicin in Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Feijen et al found that daunorubicin may be associated with reduced risk of late heart failure vs doxorubicin in survivors of childhood cancer. Study Details The study included data from 15,815 survivors of childhood cancer who survived...
BRAF V600 Mutation Appears to Be Targetable Oncogene in Some but Not All Nonmelanoma Cancers
In a phase II histology-independent basket study reported in The New England Journal of Medicine, Hyman et al found that the BRAF V600 kinase inhibitor vemurafenib (Zelboraf) exhibited activity in some but not all nonmelanoma cancers with BRAF V600 mutations. Study Details In the study, 122...
Phase II Trial Shows Greater Activity With Lenalidomide/Rituximab vs Lenalidomide in Recurrent Follicular Lymphoma
In a phase II trial (Cancer and Leukemia Group B 50401/Alliance) reported in the Journal of Clinical Oncology, Leonard et al found that the addition of rituximab (Rituxan) to lenalidomide (Revlimid) produced a higher response rate and longer time to progression than lenalidomide alone in patients...
Sham and Real Electroacupuncture Reduce Hot Flashes vs Gabapentin and Pill Placebo in Breast Cancer Survivors
In a study assessing placebo effects reported in the Journal of Clinical Oncology, Mao et al found that sham electroacupuncture produced a greater reduction in hot flashes than placebo pills and gabapentin, with the greatest reduction being achieved with real electroacupuncture. Study Details In...
Increased Risk of Cancers After Age 40 in Childhood Cancer Survivors
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Turcotte et al found that survivors of childhood cancer are at increased risk of subsequent malignant neoplasms after age 40 years. Study Details The study involved data from 3,171 survivors of...
Increased Risk of Intestinal Obstruction and Mortality in Survivors of Childhood Cancer
As reported by Madenci et al in the Journal of Clinical Oncology, an analysis from the Childhood Cancer Survivor Study showed that childhood cancer survivors are at increased risk of intestinal obstruction requiring surgery at ≥ 5 years after cancer diagnosis and poorer overall survival. Study...
Pooled Analysis Shows Improved Outcomes With Continuous vs Fixed-Duration Therapy in Newly Diagnosed Multiple Myeloma
In a pooled analysis of trials assessing novel agent-based continuous therapy vs fixed duration of therapy reported in the Journal of Clinical Oncology, Palumbo et al found that continuous therapy prolonged progression-free survival, progression-free survival-2 (time to second progression or...
Similar Outcomes With Tinzaparin vs Warfarin in Treatment of Acute Venous Thromboembolism in Patients With Active Cancer
In the phase III CATCH trial reported in JAMA, Lee et al found that the low–molecular-weight heparin tinzaparin (Innohep) did not significantly reduce the risk of recurrent venous thromboembolism vs warfarin in the treatment of acute symptomatic venous thromboembolism in patients with active...
Activity of Colony-Stimulating Factor-1 Receptor Kinase Inhibitor in Tenosynovial Giant Cell Tumors
In a phase I study reported in The New England Journal of Medicine, Tap et al found that a newly developed inhibitor of colony-stimulating factor-1 receptor (CSF1R) kinase showed activity in tenosynovial giant cell tumors. CSF1 gene expression is elevated in most such tumors. The structure of the...
Aspirin Reduces Obesity-Related Colorectal Cancer Risk in Patients With Lynch Syndrome
In an analysis of a randomized trial of aspirin in patients with Lynch syndrome reported in the Journal of Clinical Oncology, Movahedi et al found that obesity was associated with an increased risk of colorectal cancer, with the excess risk being restricted to those not receiving aspirin. ...
Integration of Mutation Status to FLIPI Improves Risk Stratification for Patients Receiving First-Line Immunochemotherapy for Follicular Lymphoma
In a study reported in The Lancet Oncology, Pastore et al found that the addition of mutation status of seven genes to the Follicular Lymphoma International Prognostic Index (FLIPI) and Eastern Cooperative Oncology Group (ECOG) performance status produced a clinicogenetic model (m7-FLIPI) with high ...
Consolidative Radiotherapy Underused in Early‑Stage Diffuse Large B-Cell Lymphoma
In a study reported in the Journal of Clinical Oncology, Vargo et al found that use of consolidative radiotherapy, which continues to decline, is associated with a survival benefit compared with multiagent chemotherapy alone in patients with early-stage diffuse large B-cell lymphoma. Study Details ...
Preclinical and Clinical Evidence of Lack of Sprouting Angiogenesis in Development of Lymph Node Metastases
In preclinical and clinical studies reported in the Journal of the National Cancer Institute, Jeong et al found a lack of sprouting angiogenesis in the formation of lymph node metastases, suggesting a potential mechanism for resistance to antiangiogenic treatments in adjuvant settings. The study...
Report of Secondary Outcomes in NSABP B-40 Indicates Improved Overall Survival With Neoadjuvant Plus Adjuvant Bevacizumab in Early Breast Cancer
The phase III NSABP B-40 (NRG Oncology) trial showed that the addition of bevacizumab (Avastin) to docetaxel-based neoadjuvant chemotherapy improved pathologic complete response rate, the primary endpoint, in patients with early HER2-negative breast cancer. In a report of secondary outcomes in The...
European Trial Indicates No Additional Benefit From Preoperative Radiotherapy Following Neoadjuvant Chemotherapy in Stage IIIA/N2 NSCLC
In a phase III trial reported in The Lancet, Pless et al in the Swiss Group for Clinical Cancer Research found that adding preoperative radiation following neoadjuvant chemotherapy did not appear to improve outcomes vs neoadjuvant chemotherapy alone in patients with stage IIIA/N2 non–small...
Introduction of Generic Aromatase Inhibitors Reduces Decline in Adherence in Medicare D Breast Cancer Patients Without Low-Income Subsidy
Adherence to aromatase inhibitor treatment for breast cancer declines over time. In a study reported in the Journal of the National Cancer Institute, Neuner et al found that introduction of generic aromatase inhibitors resulted in a reduction in decline in adherence among patients with breast...
Digital Gene Expression Cell of Origin Assay Shows High Prognostic Ability in Diffuse Large B-Cell Lymphoma
In a study reported in the Journal of Clinical Oncology, Scott et al found that the digital gene expression–based Lymph2Cx assay produced concordant cell of origin assignments in formalin-fixed paraffin-embedded tissue biopsies from patients with diffuse large B-cell lymphoma and showed high...
Study Evaluates Breast Cancer Mortality in Women With DCIS
In a study reported in JAMA Oncology, Narod et al found that the risk of breast cancer mortality was elevated in some patients with ductal carcinoma in situ compared with the general population, with the risk being higher in younger vs older women and black vs white women. Approximately half of...
Rolapitant Reduced Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
In two phase III trials reported in The Lancet Oncology, Rapoport et al found that the addition of rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in prevention of chemotherapy-induced nausea and vomiting in patients...
Rolapitant Reduced Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy or Anthracycline/Cyclophosphamide
In a phase III study reported in The Lancet Oncology, Schwartzberg et al found that the addition of rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in prevention of chemotherapy-induced nausea and vomiting in patients...
Danish Analysis Indicates Increased Risk of Late Adverse Outcomes in Patients Treated for Relapsed Disseminated Testicular Germ Cell Cancer
In a Danish analysis reported in the Journal of Clinical Oncology, Lauritsen et al found that patients with testicular germ cell cancer who survived after more than one line of treatment for disseminated disease had an increased risk of late toxicity and death resulting from causes other than germ...
Pembrolizumab Cutaneous Adverse Events May Predict Better Response
In a single-center retrospective review reported in JAMA Dermatology, Sanlorenzo et al found that cutaneous adverse events in patients receiving the anti–PD-1 agent pembrolizumab (Keytruda), currently approved for treatment of melanoma, may indicate better treatment response. Study Details...
Analysis Indicates That Tubal Ligation Is Associated With Lower Endometrial Cancer Stage at Diagnosis and Improved Survival
In an analysis from the NRG Oncology/Gynecologic Oncology Group 210 trial reported in the Journal of the National Cancer Institute, Felix et al found that tubal ligation, which should impede transtubal passage of cells, was associated with lower stage of endometrial cancer at presentation and...
Persistent HPV16 DNA in Post-Treatment Oral Rinse Associated With Poor Prognosis in HPV-Related Oropharyngeal Carcinoma
In a prospective cohort study reported in JAMA Oncology, Rettig et al found that persistent human papillomavirus (HPV) type 16 DNA in post-treatment oral rinses was associated with a poorer prognosis in patients with HPV-related oropharyngeal cancer. The study included 124 patients treated with...
Similar Survival With Salvage Surgery After Definitive Chemoradiotherapy vs Neoadjuvant Chemotherapy Followed by Esophagectomy in Esophageal Cancer
In a retrospective European study reported in the Journal of Clinical Oncology, Markar et al found that salvage esophagectomy after definitive chemoradiotherapy was associated with similar survival outcomes vs neoadjuvant chemotherapy followed by planned esophagectomy in treatment of...
Long-Term Results of Dutch CROSS Trial Indicate Continued Survival Benefit With Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Initial results of the Dutch phase III CROSS trial showed a significant 5-year overall survival benefit with the addition of neoadjuvant chemoradiotherapy to surgery after a median 45-month follow-up in patients with squamous cell carcinoma or adenocarcinoma of the esophagus or esophagogastric...
Hypofractionation of Breast Radiotherapy Associated With Reduced Acute Toxicity
In an analysis reported in JAMA Oncology, Jagsi et al found that hypofractionation of whole-breast radiotherapy was associated with reduced acute toxicity compared with conventional fractionation. Study Details The study involved data on physician-assessed toxic effects and patient-reported...
Most Stage-Specific Survival Improvement in Women With Breast Cancer Under Age 70 Is Not Explained by Tumor Size or Estrogen Receptor Status
In an analysis reported in the Journal of Clinical Oncology, Park et al found that most of the improvement in breast cancer–specific mortality observed over time in the United States is not explained by tumor size or estrogen receptor status in women aged < 70 years, suggesting a major...
POLE-Mutant and Microsatellite-Unstable Endometrial Tumors May Be Candidates for Anti–PD-1 Treatment
In a study reported in JAMA Oncology, Howitt et al found that polymerase e (POLE)-mutant and microsatellite-unstable endometrial tumors may be candidates for anti–PD-1 (programmed cell death protein 1) immunotherapy. Study Details In the study, neoantigen load was predicted on the basis of...
Adding Oxaliplatin to Preoperative Chemoradiotherapy and Postoperative Chemotherapy Improves Disease-Free Survival in Locally Advanced Rectal Cancer
Final results of the German phase III CAO/ARO/AIO-04 trial reported in The Lancet Oncology by Rödel et al showed that adding oxaliplatin to fluorouracil (5-FU)–based neoadjuvant chemoradiation and postoperative chemotherapy improved disease-free survival in patients with locally advanced ...
Identification of Risk Factors for Melanoma in Survivors of Non-Hodgkin Lymphoma
Risk for melanoma has been found to be increased in non-Hodgkin lymphoma (NHL) survivors. In a study reported in the Journal of Clinical Oncology, Lam et al found that T-cell–activating autoimmune diseases and fludarabine use were associated with an increased melanoma risk among patients with ...
International Myeloma Working Group Defines Revised International Staging System for Multiple Myeloma
As reported in the Journal of Clinical Oncology by Palumbo et al, the International Myeloma Working Group recommends the use of a revised international staging system (R-ISS) for newly diagnosed multiple myeloma that incorporates chromosomal abnormalities detected by interphase fluorescent in situ...
Reduced Short-Term Effects With Hypofractionated Whole-Breast Irradiation After Breast-Conserving Surgery
In a randomized trial reported in JAMA Oncology, Shaitelman et al found that hypofractionated whole-breast irradiation resulted in reduced short-term effects compared with conventional fractionation in women with stage 0 to II breast cancer undergoing breast-conserving surgery. Study Details In...
French Phase II Trial Suggests No Benefit of Adding Bevacizumab to Paclitaxel in Advanced Angiosarcoma
In a French phase II trial reported in the Journal of Clinical Oncology, Ray-Coquard et al found no apparent benefit of paclitaxel plus bevacizumab (Avastin) compared with weekly paclitaxel in patients with inoperable locally advanced or metastatic angiosarcoma. Study Details In this...
Susceptibility Gene Identified for Familial Nonmedullary Thyroid Cancer
As reported in The New England Journal of Medicine, Gara et al identified a germline HABP2 mutation as a susceptibility gene for familial nonmedullary thyroid cancer. Identification of HABP2 Variant In a kindred study, whole-exome sequencing was performed using peripheral blood DNA from affected...
Limited Resection Not Equivalent to Lobectomy for Survival in Older Patients With Early-Stage Lung Cancer
In an analysis reported in the Journal of Clinical Oncology, Veluswamy et al found that limited resection was not equivalent to lobectomy in overall survival among older patients with stage IA invasive adenocarcinoma or squamous cell carcinoma of the lung. Among patients with adenocarcinoma,...
Oral Contraceptives May Offer Long-Term Protection From Endometrial Cancer
In an individual-patient meta-analysis reported in The Lancet Oncology, the Collaborative Group on Epidemiological Studies on Endometrial Cancer found that oral contraceptive use was associated with long-term protection from endometrial cancer. Reduction in risk was greater for carcinomas than...
Annual Incidence of Melanoma Projected to Increase Markedly by 2030
As reported in Morbidity and Mortality Weekly Report by Guy et al, data from the Centers for Disease Control and Prevention (CDC) indicate that there were an estimated 65,647 new cases of invasive melanoma in the United States in 2011. In the absence of intervention, the annual incidence is...
Study Finds Increased Short-Term Risk for Cardiovascular Disease Mortality After Chemotherapy for Testicular Nonseminoma
In a population-based study reported in the Journal of Clinical Oncology, Fung et al found a significantly increased risk of cardiovascular disease mortality during the first year after chemotherapy for testicular nonseminoma. No increased risk of cardiovascular disease mortality after surgery was...
Addition of Docetaxel to Androgen-Deprivation Therapy Improves Survival in Metastatic Prostate Cancer
In the phase III E3805 trial reported in The New England Journal of Medicine, Sweeney et al found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median overall survival vs androgen-deprivation therapy alone in men with...
Sequencing Studies Show High Frequency of Actionable MET Mutations in Pulmonary Sarcomatoid Carcinoma
In a study reported in the Journal of Clinical Oncology by Liu et al, next-generation sequencing revealed a high frequency of actionable MET mutations in patients with pulmonary sarcomatoid carcinoma. Study Details In the study, whole-exome sequencing was used in a discovery set of 10 patients...
ASCO Statement: Improving the Evidence Base for Treating Older Adults With Cancer
Older persons are the fastest growing segment of the U.S. population and account for the majority of cancer diagnoses and deaths and the majority of cancer survivors. However, since this population is underrepresented in clinical trials, the evidence base for treating older patients is poor. As...
17-Year Follow-up Indicates Early but Not Overall Reduction in Breast Cancer Mortality With Annual Mammography Screening at Age 40-49 Years
The 17-year follow-up in the UK Age trial, reported in The Lancet Oncology by Moss et al, indicated a reduction in breast cancer mortality during the first 10 years after diagnosis but not thereafter among women invited for annual mammography screening from age 40 to 49 years compared with...
Biomarker Signature May Predict Aggressive Disease in African American Men With Prostate Cancer
In a study reported in Journal of Clinical Oncology, Yamoah et al identified a biomarker signature that may predict aggressive disease in African American men with prostate cancer. Study Details In the study, distribution of mRNA expression levels of 20 biomarkers associated with prostate cancer...
Involved-Field Radiotherapy May Be Best Option for Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
As reported by Eichenauer and colleagues in the Journal of Clinical Oncology, an analysis of long-term outcomes suggests that involved-field radiotherapy may be the best treatment option in patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma. Study Details The study involved...
